MedTrace Logo

Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma

NCT00859469 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2019-10-30

Study results available
· View outcomes & findings →

Summary

In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?

Conditions

Interventions

DRUG

Oxaliplatin

Oxaliplatin 100 mg/m2 IV infusion for 2 hours

DRUG

Gemcitabine

Gemcitabine 1000mg/m2 IV infusion for 90 minutes

Sponsors & Collaborators

Principal Investigators

  • Robert N Taub, MD, PhD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2009-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00859469 on ClinicalTrials.gov